米洛巴林治疗牙髓治疗后创伤性三叉神经病理性疼痛两例报告
本文报告两例牙髓治疗后出现咬合痛和叩痛的患者,根据国际口面疼痛分类诊断为创伤性三叉神经病理性疼痛。局部麻醉测试提示疼痛源于牙周外周区域,根管再治疗虽大幅降低视觉模拟量表评分但疼痛持续,予米洛巴林10 mg/d睡前口服后疼痛逐渐显著缓解,数个月后逐渐减量停药未见复发。
要点
- 牙髓治疗后持续咬合痛和叩痛需考虑创伤性三叉神经病理性疼痛。
- 局部麻醉测试可帮助判断疼痛源于外周而非中枢敏化。
- 米洛巴林10 mg/d睡前口服可能缓解此类神经病理性疼痛。
核心结论
- 米洛巴林可能成为牙髓治疗后创伤性三叉神经病理性疼痛的新治疗选择。
研究设计与样本
- 两例病例报告,患者因牙髓治疗后异常疼痛由初诊牙医转诊。
主要发现
- 两例患者无肿胀或根尖周透射影,但有咬合痛和叩痛,抗生素或非甾体抗炎药无效。
- 局部麻醉测试显示疼痛起源于牙周外周区域而非中枢敏化。
- 根管再治疗后视觉模拟量表评分大幅下降但疼痛持续。
- 米洛巴林10 mg/d睡前口服2周后视觉模拟量表评分逐渐显著下降。
- 数个月后逐渐减量停药,未见牙髓治疗后疼痛复发。
关键数值与推荐
- 根据国际口面疼痛分类标准排除创伤性三叉神经病理性疼痛以外的疾病。
- 米洛巴林剂量为10 mg/d,每日一次睡前服用。
临床怎么用
- 对牙髓治疗后持续咬合痛和叩痛且影像学无异常者,应想到创伤性三叉神经病理性疼痛。
- 可尝试局部麻醉测试判断疼痛来源,并依据国际口面疼痛分类进行诊断。
- 在排除其他疾病后,可考虑试用米洛巴林10 mg/d并观察2周疗效。
局限性
- 仅为两例病例报告,证据级别有限,结论需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Occlusal and percussion pain may manifest occasionally following endodontic treatment, influencing retreatment decisions. Two cases of periapical neuropathic pain, classified as post-traumatic trigeminal neuropathic pain according to the International Classification of Orofacial Pain, are presented. Although mirogabalin is effective in managing neuropathic pain, there is a lack of clinical reports on its use for occasional post-traumatic trigeminal neuropathic pain after endodontic treatment. These cases highlight clinical symptoms and successful treatment with mirogabalin for post-traumatic trigeminal neuropathic pain after endodontic treatment, providing clinicians a "take-away" lesson for improving patient condition. METHODS: The patients, referred by their primary dentist due to postendodontic abnormal pain, found no relief with antibiotics or nonsteroidal anti-inflammatory drugs. Although no findings including swelling or periapical radiolucency were observed around the tooth, they experienced occlusal and percussion pain. Local anesthetic testing showed that the pain originated from the peripheral area around the tooth rather than from central sensitization. Dental radiography and cone-beam computed tomography revealed no abnormal findings. Root canal retreatment was performed by a specialist in endodontic treatment. Although endodontic retreatment drastically decreased visual analog scale pain score, pain persisted. Based on the International Classification of Orofacial Pain criteria, diseases other than post-traumatic trigeminal neuropathic pain were excluded. Mirogabalin (10 mg/d) was prescribed once daily before bedtime. RESULTS: Visual analog scale scores gradually and drastically decreased 2 weeks after mirogabalin therapy. Several months later, no recurrence of postendodontic pain was observed after tapering off and discontinuing mirogabalin. CONCLUSIONS: These findings suggest the possibility of a new treatment method for post-traumatic trigeminal neuropathic pain after endodontic treatment.
引用
- Shimizu K, Yasukawa T, Ohara K, et al. Mirogabalin as a Therapeutic Option for Neuropathic Pain Emerging Post-endodontic Treatment: A Two-Case Report. J Endod. 2024. PMID: 38901645. doi:10.1016/j.joen.2024.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。